Works matching IS 08991987 AND DT 2004 AND VI 41 AND IP 3
Results: 5
Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogene‐induced malignant transformation.
- Published in:
- Molecular Carcinogenesis, 2004, v. 41, n. 3, p. 164, doi. 10.1002/mc.20054
- By:
- Publication type:
- Article
Tcf binding sequence and position determines β‐catenin and Lef‐1 responsiveness of MMP‐7 promoters.
- Published in:
- Molecular Carcinogenesis, 2004, v. 41, n. 3, p. 125, doi. 10.1002/mc.20049
- By:
- Publication type:
- Article
Phase II enzyme inducer, sulforaphane, inhibits UVB‐induced AP‐1 activation in human keratinocytes by a novel mechanism.
- Published in:
- Molecular Carcinogenesis, 2004, v. 41, n. 3, p. 179, doi. 10.1002/mc.20052
- By:
- Publication type:
- Article
Suppression of inducible nitric oxide synthase and cyclooxygenase‐2 in downregulating nuclear factor‐kappa B pathway by Garcinol.
- Published in:
- Molecular Carcinogenesis, 2004, v. 41, n. 3, p. 140, doi. 10.1002/mc.20050
- By:
- Publication type:
- Article
Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events.
- Published in:
- Molecular Carcinogenesis, 2004, v. 41, n. 3, p. 150, doi. 10.1002/mc.20051
- By:
- Publication type:
- Article